Results 41 to 50 of about 14,793 (172)

HIV drug resistance and treatment success in the Republic of Congo: Implications for optimized treatment

HIV Medicine, EarlyView.
Abstract Objectives Increasing rates of HIV‐1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub‐Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options.
Dominic Rauschning, Arcy Marcelin Elenga Ike, Johanna Holterhoff, Amira Stockinger, Darrel Ornelle Elion Assiana, Claujens Chastel Mfoutou Mapanguy, Freisnel Hermeland Mouzinga, Carola Horn, Isabelle Suarez, Ferdinand Heyn, Diane Alexia Fila, Hubert Banguissa, Fabien Roch Niama, Donatien Moukassa, Eva Heger, Francine Ntoumi, Clara Lehmann   +16 more
wiley   +1 more source

Retrovirus-based pseudotyped virus neutralisation assays overestimate neutralising activity in sera from participants receiving integrase inhibitors

Scientific Reports
Retroviral pseudotype-based virus neutralisation assays are widely used to estimate functional immunity, but may be unsuitable for testing human immunodeficiency virus (HIV)-infected individuals receiving integrase inhibitor treatment. We evaluated these
Mhairi J. McCormack, Patawee Asamaphan, Ellen C. Hughes, Louis Banda, Stephen Kasenda, Chris Davis, Agnieszka M. Szemiel, Amelia Crampin, Abena S. Amoah, Emma C. Thomson, Antonia Ho, Brian J. Willett   +11 more
doaj   +1 more source

Prior PrEP use and discontinuation in individuals newly diagnosed with HIV

HIV Medicine, EarlyView.
Abstract Background In settings with high uptake of HIV pre‐exposure prophylaxis (PrEP), an increasing proportion of individuals newly diagnosed with HIV report prior PrEP exposure. Understanding patterns of PrEP use, discontinuation and adherence in such settings is essential to inform future HIV prevention strategies.
Rohan Saini, Sarah Fidler, Marta Boffito, Vicky Tittle, Nicolo Girometti, Gary Whitlock, on behalf of the Dean Street Collaborative Group, Keerti Gedela, Franki Lander, Alan McOwan, Diarmuid Nugent, Sheel Patel, Sashini Payagala, Tara Suchak, Vicky Tittle, Gary Whitlock   +15 more
wiley   +1 more source

Discovery of Novel Integrase Inhibitors Acting outside the Active Site Through High-Throughput Screening

Molecules, 2019
Currently, an increasing number of drugs are becoming available to clinics for the treatment of HIV infection. Even if this targeted therapy is highly effective at suppressing viral replication, caregivers are facing growing therapeutic failures in ...
Cindy Aknin, Elena A. Smith, Christophe Marchand, Marie-Line Andreola, Yves Pommier, Mathieu Metifiot   +5 more
doaj   +1 more source

Screening for bone health in older people with HIV: Uptake and outcomes from a large UK outpatient HIV service

HIV Medicine, EarlyView.
Abstract Objectives Bone health is negatively affected in people with HIV, and the risks of osteoporosis and fragility fractures are increased. The objective of this study was to describe the characteristics of those accessing bone health screening and identify factors associated with osteoporosis.
Rhys Nicholas, Kate Alford, Colin Fitzpatrick, Jaime Vera   +3 more
wiley   +1 more source

LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs. [PDF]

PLoS Pathogens, 2012
Lens epithelium-derived growth factor (LEDGF/p75) is a cellular cofactor of HIV-1 integrase (IN) that interacts with IN through its IN binding domain (IBD) and tethers the viral pre-integration complex to the host cell chromatin.
Rik Schrijvers, Jan De Rijck, Jonas Demeulemeester, Noritaka Adachi, Sofie Vets, Keshet Ronen, Frauke Christ, Frederic D Bushman, Zeger Debyser, Rik Gijsbers   +9 more
doaj   +1 more source

Dolutegravir population pharmacokinetics in racially, sex‐ and age‐diverse and antiretroviral therapy‐experienced adults with HIV in the United States

HIV Medicine, EarlyView.
Abstract Objectives Dolutegravir (DTG) has been associated with weight gain in women with HIV, Black people with HIV and people with HIV60 years. This study aimed to characterise DTG population pharmacokinetics (PopPK) in a diverse population including these sub‐populations.
Adrian Khoei, Andrew Edmonds, Yen Chang, Catalina Ramirez, Mackenzie Vogan, Amanda Poliseno, Steven Wolinsky, Ken Ho, Todd T. Brown, Joseph B. Margolick, Jacquett Batson, Jennifer Hoffmann, Mark A. Marzinke, Mirjam‐Colette Kempf, Maria L. Alcaide, Joffi Effoe, Cecile D. Lahiri, Igho Ofotokun, Anandi N. Sheth, Stephen Gange, Audrey L. French, Bani Tamraz, Bradley E. Aouizerat, Phyllis C. Tien, Seble G. Kassaye, Jack DeHovitz, Kathryn Anastos, Kara W. Chew, Michelle Floris‐Moore, Julie B. Dumond   +29 more
wiley   +1 more source

UltRaSoUnd‐guided evaLuAtion of metabolic health in a cohort of midlife women with HIV: The URSULA study

HIV Medicine, EarlyView.
Abstract Objectives We aimed to determine the prevalence of metabolic disorders, liver steatosis and metabolic dysfunction‐associated steatotic liver disease (MASLD) in a cohort of middle‐aged women with HIV (WoWH) and to explore associations between liver steatosis, visceral fat depots and carotid atherosclerosis.
Mariacristina Poliseno, Davide Capruzzi, Antonio Cianciaruso, Nicola Colavito, Felicia Dalitto, Vincenzo Giliberti, Vittoria Lobalsamo, Giuliana Metrangolo, Marica Noviello, Alessandra Vigna, Maurizio Zarcone, Francesco Di Gennaro, Vincenzo Ostilio Palmieri, Annalisa Saracino   +13 more
wiley   +1 more source

In vitro HIV-1 LTR integration into T-cell activation gene CD27 segment and the decoy effect of modified-sequence DNA. [PDF]

PLoS ONE, 2012
Integration into the host genome is an essential step in the HIV-1 life cycle. However, the host genome sequence that is favored by HIV-1 during integration has never been documented.
Rei Ohmori, Tatsuaki Tsuruyama
doaj   +1 more source

Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study

HIV Medicine, EarlyView.
Abstract Objectives We have shown that semaglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), is a highly effective therapy for metabolic dysfunction‐associated steatotic liver disease (MASLD) in people with HIV (PWH). The OWLiver® metabolomics algorithms allow non‐invasive MASLD severity staging without liver biopsy, but the use of ...
Jordan E. Lake, Douglas W. Kitch, Amy Kantor, Rebeca Mayo, Pablo Belaunzaran‐Zamudio, Carl J. Fichtenbaum, Todd T. Brown, Kathleen E. Corey, Fred Sattler, Kristine M. Erlandson   +9 more
wiley   +1 more source